Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation

Drug Safety

Volumn 31, Issue 1, 2008, Pages 67-77

  Kubitza, Dagmar ^a   Mueck, Wolfgang ^a   Becka, Michael ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

QT interval prolongation, drug induced; Research and development; Rivaroxaban, adverse reactions

Indexed keywords

MOXIFLOXACIN; PLACEBO; RIVAROXABAN;

ADULT; AGED; ANALYSIS OF COVARIANCE; APPENDICITIS; APPLICATION SITE BLEEDING; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VITAL SIGN;

EID: 37549017626     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831010-00006     Document Type: Article

References (25)

1. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 429S-56S
2. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 513S-48S
3. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 204S-33S
4. Ansell J, Bergqvist D. Current options in the prevention of thromboembolic disease. Drugs 2004; 64 Suppl. 1: 1-5
5. Bayer HealthCare AG, data on file, 2005
6. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78 (4): 412-21
7. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61 (12): 873-80
8. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3 (11): 2479-86
9. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4 (1): 121-8
10. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 2374-81
11. Agnelli G, Gallus A, Goldhaber S, et al. Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT dose-ranging study [abstract]. Eur Heart J 2006; 27 (Abstract Suppl.): 761
12. Buller HR. Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding study [abstract]. Eur Heart J 2006; 27 Suppl.: 761
13. Recanatini M, Poluzzi E, Masetti M, et al. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005; 25 (2): 133-66
14. Antzelevitch C, Sun ZQ, Zhang ZQ, et al. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996; 28 (7): 1836-48
15. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999; 33 (1): 22-6
16. Thomas D, Wu K, Kathofer S, et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol 2003; 139 (3): 567-74
17. Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol: a review of the literature and practical guidelines for use. Expert Opin Drug Saf 2003; 2 (6): 543-7
18. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36: 233-52
19. European Medicines Agency. ICH E14 The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (CHMP/ICH/2/04) [online]. Available from URL: http://www.emea.eu.int/pdfs/human/ ich/000204en.pdf [Accessed 2007 Oct 5]
20. Shah RR. Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J Electrocardiol 2005; 38 (1): 10-8
21. Demolis JL, Kubitza D, Tenneze L, et al. Effect of a single oral dose of moxifloxacin (400mg and 800mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000; 68 (6): 658-66
22. Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 2002; 16 (2): 147-56
23. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 338S-400S
24. 14C]BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rat, dog and human [abstract no. 196]. Drug Metab Rev 2004; 36 Suppl. 1: 98
25. Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003; 73 (4): 292-303